Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers  

作　　者：Gavin P.Dowling Gordon R.Daly Aisling Hegarty Michael Flanagan Mihaela Ola Ramón Fallon Sinéad Cocchiglia Vikrant Singh Katherine M.Sheehan Fiona Bane Jason McGrath Louise Watson Sandra Hembrecht Bryan Hennessy Patrick G.Morris Arnold D.K.Hill Damir Varešlija Leonie S.Young 

机构地区：[1]Department of Surgery,RCSI University of Medicine and Health Sciences,Dublin,Ireland [2]Department of Surgery,Beaumont Hospital,Dublin,Ireland [3]Beaumont RCSI Cancer Centre,Beaumont Hospital,Dublin,Ireland [4]Department of Pathology,RCSI University of Medicine and Health Sciences,Dublin,Ireland [5]School of Pharmacy and Biomolecular Sciences,RCSI University of Medicine and Health Sciences,Dublin,Ireland

出　　处：《Cancer Communications》2025年第2期198-202,共5页癌症通讯(英文)

基　　金：support from Science Foundation Ireland Frontiers for the Future Award(19/FFP/6443);Science Foundation Ireland Strategic Partnership Program,Precision Oncology Ireland(18/SPP/3522)(L.S.Y.);Breast Cancer Now Fellowship Award with the generous support of Walk the Walk(2019AugSF1310)(D.V.);Science Foundation Ireland(20/FFP-P/8597)(D.V.);Breast Cancer Ireland program Grant(18239A01)(L.S.Y.).

摘　　要：The expression of estrogen receptor(ER)and human epidermal growth factor receptor-2(HER2)in breast cancer can change in response to treatment and pivotally influence tumor behavior and clinical management[1].Receptor discordance has been observed at various distant metastatic site(bone,lung,liver,and brain),with a routine loss of ER and gains in HER2 reported[2].This receptor discordance can influence tumor responsiveness to both HER2 inhibitor and endocrine therapies.Although the mechanisms underlying receptor expression changes are not fully understood,we recently reported gains in ESR1 promoter hypermethylation as a potential driver of ER loss during disease progression[3].In this study,mechanisms underlying altered receptor expression and associated disease outcomes were examined following neoadjuvant trastuzumab treatment.

关 键 词：alterations HER2 BREAST 

分 类 号：R73[医药卫生—肿瘤]